Further characterization of post-CAR leukaemia demonstrated that earlier relapses maintained pre-B phenotype with isolated CD19 loss, whereas later relapses acquired multiple phenotypic changes including loss of additional B-cell markers (Fig. 2d). This evidence concerns the gene CD19 and leukemia.